Biotech firm Reneuron becomes latest to quit AIM as it battles for survival

Biotech firm Reneuron Group has become the latest company to exit from the London Stock Exchange’s AIM as it continues to fight for its life after entering administration. The Welsh company, which was first floated on London’s junior market in 2005, said it did not believe it would be able to raise enough funds to [...]